atypical antipsychotic-induced parkinsonism: a patient case with cyp enzyme implications

Clicks: 380
ID: 183067
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 122 articles by views in food control

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Objective: To report a case of Parkinsonism potentially caused by neuroleptic medications. Summary: The case analyzed is that of a 57-year-old male patient referred to a pharmacotherapy service by a neurologist after organic causes of tremor had been ruled out. Iatrogenic cause was suspected and referral expectation was to identify the offending agent or agents and propose alternative therapy. Conclusion: This case illustrates iatrogenic risk associated with neuroleptic medications while illustrating mechanisms of drug interaction via CYP enzymes that can lead to iatrogenic disease. Abbreviations: DIP = Drug-induced Parkinsonism; MTM = Medication Therapy Management; PD = Parkinson’s Disease   Type: Clincial Experience
Reference Key
figura2017innovationsatypical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Carla Dolci Figura;Michael Schuh
Journal food control
Year 2017
DOI
10.24926/iip.v8i2.507
URL
https://pubs.lib.umn.edu/index.php/innovations/article/view/507
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.